Private Equity Looks To Small, Mid-Size Drug Makers Risking Growth (India)
This article was originally published in PharmAsia News
Private-equity firms appear increasingly interested in supporting outsourcing ventures among small and mid-size pharmaceutical companies. According to Dr. Sandeep Singhai of Sequoia Capital, that area of drug making is growing faster than growth in the established sectors, so his company is investing in those smaller firms that seek to become major players, despite the added risk of doing so. Another investor notes those types of drug makers already are into contract manufacturing and outsourcing, areas that hold huge potential. (Click here for more
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.